CI stock forecast, quote, news & analysis

Key Takeaways

• Cigna Group shares gained roughly 9.7% over the trailing 30 days, rising from about $271.83 to near $298, before pulling back from a 52-week high of $316.27 reached on October 22.
• The advance was supported by strong second-quarter results, a raised 2026 earnings outlook, and a well-received Investor Day, while profit-taking and renewed PBM and regulatory scrutiny drove the recent retreat.
• Third-quarter 2026 results are scheduled for release on November 5, 2026, with analysts projecting earnings of about $7.46 per share, down from $7.83 in the prior-year quarter.
• Cigna's "Lead to One" strategy, a $3 billion modernization program, and a 10%–14% adjusted EPS growth algorithm through 2030 anchor the company's long-term narrative.
• The stock trades at a forward price-to-earnings multiple near 8–9x with a dividend yield around 2.2%, reflecting a value-oriented profile relative to managed care peers.
• Analyst consensus remains a Buy, with an average price target near $342, though recent ratings have ranged from Hold to Buy.
• For deeper detail on the stock, explore Cigna's Price Targets, Earnings, and Forecast pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are approaching the market.

Current Market Snapshot

Cigna Group shares closed near $298.23 on October 30, 2026, after a volatile stretch that saw the stock climb to a 52-week intraday high of $316.27 on October 22 before giving back roughly 5% over the following sessions. The pullback coincided with profit-taking after a sharp multi-week run and renewed political and regulatory attention on health insurers and pharmacy benefit managers. Despite the retreat, the stock remains higher by approximately 9.7% over the trailing 30 days, a move that underscores renewed investor interest in a name that had lagged the broader market for much of the year.

Cigna Group (CI) Business Overview and Competitive Position

The Cigna Group is a global health company headquartered in Bloomfield, Connecticut, operating through two primary divisions. Evernorth Health Services — which includes pharmacy benefit management (Express Scripts), specialty pharmacy, and care services — generates the largest share of revenue, while Cigna Healthcare provides medical plans and coordinated health solutions across commercial and international markets. The company maintains customer relationships in more than 30 markets and jurisdictions. Key growth drivers include specialty pharmacy expansion, biosimilar adoption, and a transition toward a transparent, rebate-free pharmacy model, while medical cost management and customer retention remain important competitive considerations.

Recent Developments Driving CI

Several verified developments shaped Cigna's stock over the trailing 30 days. The company's September 30 Investor Day introduced its "Lead to One" vision, a $3 billion multi-year modernization and productivity initiative, and a long-term target of 10%–14% adjusted EPS compound annual growth through 2030. On October 6, Cigna Healthcare launched Health Sense, a personalized support model aimed at improving affordability and outcomes, initially focused on oncology and cardiometabolic conditions. The company also declared a quarterly dividend of $1.56 per share on October 28. On the analyst front, ratings were mixed, with firms such as Bernstein and RBC maintaining Buy/Outperform views while others, including Leerink and Evercore ISI, held at Hold. The pullback from the October 22 high coincided with a House investigation involving major pharmacy benefit managers and renewed scrutiny of insurers over Affordable Care Act coverage, contributing to sector-wide caution. Second-quarter results, reported in late July, showed revenue up 7% to $71.7 billion and adjusted EPS of $7.78, prompting management to raise its full-year 2026 adjusted EPS outlook to at least $30.45.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. While Tickeron offers hundreds of bots that trade thousands of tickers, only the top-performing and most relevant strategies appear in this section, giving traders a streamlined view of what is currently working. The bots vary widely in strategy, timeframe, and performance metrics, allowing users to compare approaches across momentum, swing, and other algorithmic styles. It is a useful starting point for investors interested in systematic, data-driven trading ideas.

2026 Outlook and What Investors Should Watch

Looking ahead, investors are likely to monitor Cigna's November 5 third-quarter earnings release for confirmation of its adjusted EPS trajectory and any updates to the 2026 outlook, given analyst expectations for a year-over-year earnings decline on a reported basis. Key themes include the progress of the $3 billion modernization program, adoption of the rebate-free Signature pharmacy model, and specialty pharmacy growth, which has been a principal earnings driver. Medical cost trends — Cigna's medical care ratio rose to 84.5% in the second quarter from 83.2% a year earlier — and ongoing regulatory scrutiny of pharmacy benefit managers and health insurers represent the most visible risks. Valuation remains compressed relative to historical levels, but execution on cost management, customer retention, and productivity savings will be central to the stock's direction through the rest of 2026 and into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations